News

Massive Trading Activity Spotted in Tempus AI (TEM) Options

Massive Trading Activity Spotted in Tempus AI (TEM) Options

Unprecedented Trading Interest in Tempus AI Options

Investors with significant capital are showing a strong bullish outlook on Tempus AI (TEM). This surge in trading activity is something every retail trader should pay attention to.

Identifying Smart Money Moves

Today, we observed notable trends in the options market for Tempus AI, highlighting the actions of big-money traders. These insights were made possible through options trade history.

Understanding the Investor Sentiment

While we cannot identify the exact entities behind these movements, the scale of the trades often suggests that someone possesses critical information about Tempus AI's future developments.

Analyzing Unusual Options Activity

Our analysis using advanced options scanners revealed 22 uncommon trades occurring in the Tempus AI marketplace. This level of activity is certainly rare and signifies significant investor interest.

Breakdown of Trading Trends

The sentiment among high-value traders is split, with approximately 63% indicating bullish positions and 27% bearing bearish outlooks. This raises the stakes for those involved in Tempus AI's trading scene.

Overview of Current Options Activity

In total, 22 trades were examined, revealing a notable balance between call and put options. Specifically, 5 put options accounted for total trades of $210,365, while 17 call options represented a more significant total of $831,833.

The Price Target Scenario

Taking into consideration both the volume and open interest observed in these options, it appears that whale investors have set their sights on a price range between $35.00 and $100.00 for Tempus AI over the past three months. This could hint at anticipated growth or strategic shifts within the company.

Volume & Open Interest Trends

The average open interest for Tempus AI options currently stands at 2,041.93, with a trading volume peaking at 2,966.00. This traction illustrates the traders’ confidence in high-value calls and puts positioned between the $35.00 to $100.00 strike price range over the last month.

Tempus AI Options Activity: A 30-Day Overview

Examining Notable Options Trades

Several noteworthy options trades have taken place recently. These trades span across a variety of expiration dates, showing what high-capital traders are willing to stake for potential profit.

About Tempus AI Inc

Tempus AI Inc focuses on integrating advanced technology within the healthcare sector. The company has developed the Tempus Platform, which is designed to eliminate data silos and transform healthcare data into actionable insights. Leveraging artificial intelligence, including generative AI, Tempus aims to enhance diagnostic accuracy and personalization for laboratory tests.

Tempus AI's Price Performance and Analyst Insights

  • The stock is currently trading at $59.29, reflecting a decrease of 4.37%.
  • Trading metrics indicate that the stock itself is in a neutral state, resting between the overbought and oversold territories.
  • An upcoming earnings report is anticipated within the next ten days, potentially signaling future market direction.

Professional Analyst Ratings for Tempus AI

In recent evaluations, analysts set an average target price of $75.00 for Tempus AI, suggesting optimism regarding its future performance. One analyst has maintained a buy rating, foreseeing continued positive trends.

Navigating the Options Market with Insight

Engaging with options trading can be complex and risky, yet it offers avenues for potentially lucrative returns. Knowledgeable investors often reduce these risks by committing to continuous education, strategically adjusting trades, and closely monitoring market trends.

Frequently Asked Questions

What is the current sentiment surrounding Tempus AI options?

Currently, the sentiment is predominantly bullish, with around 63% of trades indicating a positive outlook.

What are the recent price targets set for Tempus AI?

The price targets set by investors range between $35.00 and $100.00 based on recent transactions and analyses.

How has Tempus AI's stock price moved lately?

As of now, Tempus AI's stock is priced at $59.29, representing a decline of 4.37% over recent trading sessions.

What tools are used to analyze Tempus AI options activity?

Advanced options scanners track volumes and trades in real time, providing insights into unusual trading patterns for Tempus AI.

Why is understanding options activity important for investors?

Understanding options activity can reveal investor sentiment and potential future movements in stock prices, allowing for more informed trading decisions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 176

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 121

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 228

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 138

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 206

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 201

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 136

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 531

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 110

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading

Top 5 Most Recently Viewed Articles

Massive Trading Activity Spotted in Tempus AI (TEM) Options

Updated Category News Views 292

Unprecedented Trading Interest in Tempus AI Options Investors with significant capital are showing a strong bullish outlook on Tempus AI (TEM). This surge in trading activity is something every retail trader should pay attention to. Identifying Smart Money Moves Today, we observed notable trends in the options market for Tempus AI, highlighting the actions of big-money...

Continue Reading
Endeavour Mining Sees Significant Stake Notification from BlackRock

Updated Category News Views 143

Endeavour Mining and Major Shareholding Update Endeavour Mining plc is making headlines with its latest update regarding shareholders. Recently, the company received a notable notification from BlackRock, Inc., one of the world’s leading investment management firms. This announcement highlights BlackRock's interests in Endeavour Mining, showcasing the ongoing...

Continue Reading
Adverity Unveils Innovative Data Quality Suite for Clients

Updated Category News Views 188

Adverity launched its Data Quality Suite a while back, promising to revolutionize how businesses tackle data management. But let’s dig deeper—what’s the real deal here? Data Quality: A Marketing Essential or Just Noise? In this digital mess we call life, clean data isn’t just a luxury; it’s an absolute necessity. Back then, marketing and analytics teams faced a...

Continue Reading
Strengthening Medical Connections Between U.S. and Jordan

Updated Category News Views 225

Strengthening Medical Collaborations Dr. Maen Hussein, a talented medical oncologist and hematologist, recently held an important meeting with King Abdullah II of Jordan. This gathering aimed to enhance the collaboration between medical professionals in both the United States and Jordan, showcasing the commitment to elevate healthcare standards through shared knowledge...

Continue Reading
Alphabet's Stock Outlook Amid DOJ Challenges: Key Insights

Updated Category News Views 101

Alphabet's Price Target Change: Implications Recently, Evercore ISI adjusted its price target for Alphabet Inc. (NASDAQ: GOOGL), reducing it from $225 to $200. Even with this decrease, Evercore retains an Outperform rating for the stock. This change signals growing concerns over the ongoing antitrust trials led by the Department of Justice (DOJ), which could heavily...

Continue Reading